FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2755966470> ?p ?o ?g. }

• W2755966470 endingPage "352" @default.
• W2755966470 startingPage "1" @default.
• W2755966470 abstract "At the time of publication of the most recent National Institute for Health and Care Excellence (NICE) guidance [technology appraisal (TA) 32] in 2002 on beta-interferon (IFN-β) and glatiramer acetate (GA) for multiple sclerosis, there was insufficient evidence of their clinical effectiveness and cost-effectiveness.To undertake (1) systematic reviews of the clinical effectiveness and cost-effectiveness of IFN-β and GA in relapsing-remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS) and clinically isolated syndrome (CIS) compared with best supportive care (BSC) and each other, investigating annualised relapse rate (ARR) and time to disability progression confirmed at 3 months and 6 months and (2) cost-effectiveness assessments of disease-modifying therapies (DMTs) for CIS and RRMS compared with BSC and each other.Searches were undertaken in January and February 2016 in databases including The Cochrane Library, MEDLINE and the Science Citation Index. We limited some database searches to specific start dates based on previous, relevant systematic reviews. Two reviewers screened titles and abstracts with recourse to a third when needed. The Cochrane tool and the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) and Philips checklists were used for appraisal. Narrative synthesis and, when possible, random-effects meta-analysis and network meta-analysis (NMA) were performed. Cost-effectiveness analysis used published literature, findings from the Department of Health's risk-sharing scheme (RSS) and expert opinion. A de novo economic model was built for CIS. The base case used updated RSS data, a NHS and Personal Social Services perspective, a 50-year time horizon, 2014/15 prices and a discount rate of 3.5%. Outcomes are reported as incremental cost-effectiveness ratios (ICERs). We undertook probabilistic sensitivity analysis.In total, 6420 publications were identified, of which 63 relating to 35 randomised controlled trials (RCTs) were included. In total, 86% had a high risk of bias. There was very little difference between drugs in reducing moderate or severe relapse rates in RRMS. All were beneficial compared with BSC, giving a pooled rate ratio of 0.65 [95% confidence interval (CI) 0.56 to 0.76] for ARR and a hazard ratio of 0.70 (95% CI, 0.55 to 0.87) for time to disability progression confirmed at 3 months. NMA suggested that 20 mg of GA given subcutaneously had the highest probability of being the best at reducing ARR. Three separate cost-effectiveness searches identified > 2500 publications, with 26 included studies informing the narrative synthesis and model inputs. In the base case using a modified RSS the mean incremental cost was £31,900 for pooled DMTs compared with BSC and the mean incremental quality-adjusted life-years (QALYs) were 0.943, giving an ICER of £33,800 per QALY gained for people with RRMS. In probabilistic sensitivity analysis the ICER was £34,000 per QALY gained. In sensitivity analysis, using the assessment group inputs gave an ICER of £12,800 per QALY gained for pooled DMTs compared with BSC. Pegylated IFN-β-1 (125 µg) was the most cost-effective option of the individual DMTs compared with BSC (ICER £7000 per QALY gained); GA (20 mg) was the most cost-effective treatment for CIS (ICER £16,500 per QALY gained).Although we built a de novo model for CIS that incorporated evidence from our systematic review of clinical effectiveness, our findings relied on a population diagnosed with CIS before implementation of the revised 2010 McDonald criteria.DMTs were clinically effective for RRMS and CIS but cost-effective only for CIS. Both RCT evidence and RSS data are at high risk of bias. Research priorities include comparative studies with longer follow-up and systematic review and meta-synthesis of qualitative studies.This study is registered as PROSPERO CRD42016043278.The National Institute for Health Research Health Technology Assessment programme." @default.
• W2755966470 created "2017-09-25" @default.
• W2755966470 creator A5005183724 @default.
• W2755966470 creator A5007914769 @default.
• W2755966470 creator A5009352598 @default.
• W2755966470 creator A5024923244 @default.
• W2755966470 creator A5031812482 @default.
• W2755966470 creator A5033232150 @default.
• W2755966470 creator A5033450071 @default.
• W2755966470 creator A5034663755 @default.
• W2755966470 creator A5039185864 @default.
• W2755966470 creator A5059338067 @default.
• W2755966470 creator A5067383775 @default.
• W2755966470 creator A5083154337 @default.
• W2755966470 creator A5086633752 @default.
• W2755966470 creator A5089837795 @default.
• W2755966470 date "2017-09-01" @default.
• W2755966470 modified "2023-10-17" @default.
• W2755966470 title "Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation" @default.
• W2755966470 cites W1137165251 @default.
• W2755966470 cites W1512495229 @default.
• W2755966470 cites W1529192025 @default.
• W2755966470 cites W1549815892 @default.
• W2755966470 cites W1559429315 @default.
• W2755966470 cites W1562781549 @default.
• W2755966470 cites W1580917658 @default.
• W2755966470 cites W1625126257 @default.
• W2755966470 cites W1657604788 @default.
• W2755966470 cites W1666292467 @default.
• W2755966470 cites W1852815626 @default.
• W2755966470 cites W1868773492 @default.
• W2755966470 cites W1908392151 @default.
• W2755966470 cites W1943094391 @default.
• W2755966470 cites W1964054863 @default.
• W2755966470 cites W1964291521 @default.
• W2755966470 cites W1967507425 @default.
• W2755966470 cites W1967643209 @default.
• W2755966470 cites W1967724489 @default.
• W2755966470 cites W1967838438 @default.
• W2755966470 cites W1967990636 @default.
• W2755966470 cites W1968871099 @default.
• W2755966470 cites W1969682776 @default.
• W2755966470 cites W1970835952 @default.
• W2755966470 cites W1973550674 @default.
• W2755966470 cites W1974650462 @default.
• W2755966470 cites W1974859486 @default.
• W2755966470 cites W1977599025 @default.
• W2755966470 cites W1979005856 @default.
• W2755966470 cites W1980138833 @default.
• W2755966470 cites W1982172577 @default.
• W2755966470 cites W1983841278 @default.
• W2755966470 cites W1983999022 @default.
• W2755966470 cites W1985346878 @default.
• W2755966470 cites W1986008612 @default.
• W2755966470 cites W1986319272 @default.
• W2755966470 cites W1988586000 @default.
• W2755966470 cites W1989186792 @default.
• W2755966470 cites W1990040006 @default.
• W2755966470 cites W1990918979 @default.
• W2755966470 cites W1991169670 @default.
• W2755966470 cites W1993814781 @default.
• W2755966470 cites W1994469616 @default.
• W2755966470 cites W1997880566 @default.
• W2755966470 cites W1997983592 @default.
• W2755966470 cites W1998436005 @default.
• W2755966470 cites W2000986637 @default.
• W2755966470 cites W2001766826 @default.
• W2755966470 cites W2001781527 @default.
• W2755966470 cites W2004076487 @default.
• W2755966470 cites W2005506388 @default.
• W2755966470 cites W2005611486 @default.
• W2755966470 cites W2006791654 @default.
• W2755966470 cites W2008576914 @default.
• W2755966470 cites W2008732434 @default.
• W2755966470 cites W2009701030 @default.
• W2755966470 cites W2010432945 @default.
• W2755966470 cites W2010588274 @default.
• W2755966470 cites W2010699829 @default.
• W2755966470 cites W2011324376 @default.
• W2755966470 cites W2012040225 @default.
• W2755966470 cites W2014127183 @default.
• W2755966470 cites W2014945831 @default.
• W2755966470 cites W2015653058 @default.
• W2755966470 cites W2015684075 @default.
• W2755966470 cites W2019009797 @default.
• W2755966470 cites W2019028932 @default.
• W2755966470 cites W2019632979 @default.
• W2755966470 cites W2019983151 @default.
• W2755966470 cites W2020104367 @default.
• W2755966470 cites W2023102395 @default.
• W2755966470 cites W2023555055 @default.
• W2755966470 cites W2024029476 @default.
• W2755966470 cites W2026664593 @default.
• W2755966470 cites W2027723241 @default.
• W2755966470 cites W2029613564 @default.
• W2755966470 cites W2030113529 @default.
• W2755966470 cites W2030592068 @default.
• W2755966470 cites W2034831904 @default.

• next